サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1594836

アレルギー治療の世界市場-2024-2031

Global Allergy Treatment Market - 2024-2031

出版日
ページ情報
英文 181 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
アレルギー治療の世界市場-2024-2031
出版日: 2024年11月21日
発行: DataM Intelligence
ページ情報: 英文 181 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

世界のアレルギー治療市場は、2023年に250億3,000万米ドルに達し、2031年には380億4,000万米ドルに達すると予測され、予測期間2024年～2031年のCAGRは5.4%で成長する見込みです。

アレルギーとは、アレルゲンとして知られる通常は無害な化学物質に対する免疫系の過敏反応です。これらの反応は、免疫系がこれらの無害な化学物質を脅威として誤って認識し、過剰な免疫学的反応が生じることで生じる。アレルギー治療には、アレルギー反応の症状を管理し、重症度を下げるための治療法が数多く含まれています。主なアプローチには、アレルゲンの回避、薬物療法、免疫療法などがあります。

世界中でアレルギーの有病率が増加していることが、予測期間中の市場を牽引しています。有病率の増加により、治療に対する需要が増加し、それが市場を促進します。例えば、Global Allergy and Airways Patient Platformによると、アレルギー疾患の世界の有病率は先進国と発展途上国の両方で急速に増加しています。アレルギー疾患の世界的有病率は着実に増加しており、現在、世界人口の約30～40％が1つ以上のアレルギー疾患に苦しんでいます。

市場力学：

促進要因

世界のアレルギー有病率の増加

世界のアレルギー治療市場は、アレルギーの有病率の増加によって大きく牽引されています。喘息やアレルギー性鼻炎などの呼吸器アレルギー、食物アレルギー、皮膚アレルギーなど、アレルギー疾患は世界中で増加傾向にあります。この急増は、人々がより多くのアレルゲンにさらされるようになった公害の増加、都市化、ライフスタイルの変化などの環境的原因によるものと考えられます。

さらに、世界保健機関（WHO）の統計によると、世界中で数億人が鼻炎に苦しみ、3億人以上が喘息にかかっていると推定されており、これらの人々とその家族の生活の質を低下させ、社会の社会経済的福祉に悪影響を及ぼしています。米国アレルギー喘息免疫学会によると、世界中の学童の1つ以上の一般的なアレルゲンに対する感作率は、現在40％から50％に近づいています。世界全体では、18歳から44歳の25.7％が季節性アレルギーを持っていると報告されています。

さらに、World Allergy Organization Journalによれば、花粉症としても知られるアレルギー性鼻炎は、先進国、発展途上国を問わず、世界的に公衆衛生上の重大な問題です。世界的に、アレルギー性鼻炎は4億人以上が罹患しており、有病率は成人で10％から30％、小児では40％以上です。アレルギーの有病率の増加により、アレルギー治療治療薬の需要が増加しており、アレルギー治療市場を牽引しています。

アレルギー治療薬に伴う副作用

アレルギー治療薬に関連する副作用などの要因が市場を阻害すると予想されます。抗ヒスタミン薬は、眠気、口渇、目のかすみ、排尿困難、頭痛、めまい、気分が悪くなる、下痢などの副作用を引き起こします。充血除去薬は、睡眠障害、頭痛、血圧上昇、イライラなどの副作用を引き起こします。薬物アレルギーの大部分は治療可能であるが、時に重篤な喘息、アナフィラキシー、死亡を引き起こすことがあります。こうした副作用は市場の妨げとなり、アレルギー治療市場の抑制要因となっています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 世界中でアレルギーの罹患率が増加
    • 抑制要因
      • 薬に関連する副作用
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • アンメットニーズ
  • PESTEL分析
  • 特許分析
  • SWOT分析

第6章 アレルギーの種類別

  • 目のアレルギー
  • 食物アレルギー
  • 皮膚アレルギー
  • 喘息
  • 鼻炎
  • その他

第7章 治療の種類別

  • 抗アレルギー薬
  • 免疫療法

第8章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • その他

第9章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第10章 競合情勢

  • 競合シナリオ
  • 市況・シェア分析
  • M&A分析

第11章 企業プロファイル

  • GlaxoSmithKline plc
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
  • Teva Pharmaceutical Industries Ltd.
  • Stallergenes Greer
  • Allergy Therapeutics
  • Sanofi
  • Sumitomo Pharma Inc.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • F.Hoffman-La Roche
  • Abbvie Inc.

第12章 付録

目次
Product Code: PH1497

Overview

The global allergy treatment market reached US$ 25.03 billion in 2023 and is expected to reach US$ 38.04 billion by 2031, growing at a CAGR of 5.4% during the forecast period 2024-2031.

Allergy is a hypersensitive reaction of the immune system to normally harmless chemicals known as allergens. These reactions arise when the immune system incorrectly perceives these harmless chemicals as threats, resulting in an excessive immunological response. Allergy treatment includes a number of treatments for managing symptoms and lowering the severity of allergic reactions. The primary approaches include allergen avoidance, usage of medication, and immunotherapy.

The increasing prevalence of allergies across the globe drives the market over the forecast period. Due to increasing prevalence, the demand for the treatment increases which propels the market. For instance, according to the Global Allergy and Airways Patient Platform, The global prevalence of allergy disorders is rapidly increasing in both developed and developing countries. The global prevalence of allergic disorders has steadily increased, with approximately 30-40% of the world's population now suffering from one or more allergic conditions.

Market Dynamics: Drivers

Increasing prevalence of allergies across the globe

The global allergy treatment market is majorly driven by the increasing prevalence of allergies. Allergic disorders are on the rise worldwide, including respiratory allergies (such as asthma and allergic rhinitis), food allergies, and skin allergies. This surge can be attributed to environmental causes such as increased pollution, urbanization, and lifestyle changes that expose people to more allergens.

Moreover, according to World Health Organization (WHO) statistics, hundreds of millions of people worldwide suffer from rhinitis, and more than 300 million are estimated to have asthma, reducing the quality of life for these people and their families and negatively impacting society's socioeconomic welfare. According to the American Academy of Allergy, Asthma & Immunology, Sensitization rates to one or more common allergens among schoolchildren worldwide are now approaching 40%-50%. Globally, 25.7% of persons aged 18 to 44 reported having a seasonal allergy.

Moreover, according to the World Allergy Organization Journal, allergic rhinitis, also known as hay fever, is a significant public health concern worldwide, affecting both developed and developing countries. Globally, allergic rhinitis affects more than 400 million people, with prevalence rates between 10% and 30% among adults and over 40% among children. Due to the increasing prevalence of allergies, the demand for allergy treatment medication has increased and it drives the allergy treatment market.

Side effects associated with allergy treatment drugs

Factors such as side effects associated with allergy treatment drugs are expected to hamper the market. The antihistamines cause side effects such as drowsiness, dry mouth, blurred vision, difficulty urinating, headaches, dizziness, feeling sick, and diarrhea. The decongestants cause side effects such as trouble sleeping, headaches, increased blood pressure, and irritability. The majority of drug allergies are treatable, although they can occasionally cause severe asthma, anaphylaxis, or death. These side effects hamper the market and act as a restraint for the allergy treatment market.

Segment Analysis

The global allergy treatment market is segmented based on allergy type, treatment type, distribution channel, and region.

Allergy Type:

Asthma is expected to dominate the global allergy treatment market share.

The asthma segment holds a major portion of the global allergy treatment market share and is expected to continue to hold a significant portion of the global allergy treatment market share during the forecast period. The increasing prevalence of asthma makes asthma the most dominating segment in the global allergy treatment market. As the asthma prevalence increases, the demand for treatment medication increases and leads to market growth.

For instance, according to the Global Initiative for Asthma, Asthma is one of the most common chronic non-communicable diseases, affecting over 260 million people and accounting for over 450000 deaths annually worldwide, the majority of which are preventable.

Rhinitis segment is fastest growing segment in global allergy treatment market.

The rhinitis segment is the fastest-growing segment in the global allergy treatment market share during the forecast period. The gradual increase of rhinitis these days makes rhinitis the fastest-growing segment in the global allergy treatment market.

For instance, according to the World Allergy Organization Journal, allergic rhinitis affects more than 400 million people, with prevalence rates between 10% and 30% among adults and over 40% among children.

Treatment Type:

Anti-allergy drugs segment is expected to dominate the global allergy treatment market share.

The integrated monitoring systems segment holds a major portion of the global allergy treatment market share and is expected to continue to hold a significant portion of the global allergy treatment market share during the forecast period.

Anti-allergy drugs are used to treat symptoms caused by allergic reactions. These reactions happen when the immune system overreacts to normally harmless chemicals called allergens, which include pollen, pet dander, and certain foods. When an allergen is encountered, the immune system releases molecules like histamine, causing symptoms such as sneezing, itching, and nasal congestion. The anti-allergy drugs are expected to dominate the market due to their versatility and efficiency in reducing allergies.

Immunotherapy segment is the fastest growing segment in the global allergy treatment market share.

The immunotherapy features segment is the fastest growing segment in the global allergy treatment market share. The increasing awareness among people regarding immunotherapy and increased research activities make immunotherapy the fastest growing segment.

Immunotherapy has emerged as a key strategy in allergy treatment, with the goal of altering the immune system's response to allergens substances that cause allergic reactions. Unlike standard allergy drugs, which only treat symptoms, immunotherapy aims to target the root problem by gradually desensitizing the immune system to specific allergens.

For instance, in October 2024, Curex announced the launch of its unique at-home Sublingual Immunotherapy (SLIT) program for food allergies. This new service seeks to enable people with food allergies to safely and conveniently complete clinical desensitization at home.

Geographical Analysis

North America is expected to hold a significant position in the global allergy treatment market share.

North America region is expected to hold the largest market share over the forecast period. The rising incidence of chronic diseases, and recent launches, in this region, help to propel the market. The presence of top players, the increasing prevalence of allergies, and recent launches and approvals in the North American market helped to propel the market in this region.

For instance, in August 2024, The United States Food and Drug Administration (FDA) approved the first nasal spray for treating anaphylaxis, a severe and life-threatening allergic reaction that requires prompt medical attention, as well as an injection of epinephrine, a hormone shot that fights the allergen. The increasing prevalence of allergies is also one of the major driving factors. For instance, according to the American Academy of Allergy, Asthma & Immunology, roughly 7.8% of people 18 and over in the U.S. have hay fever.

Moreover, according to the American College of Allergy, Asthma & Immunology, asthma and allergic illnesses, such as allergic rhinitis (hay fever), food allergies, and eczema, affect people of all ages throughout the United States. Asthma affects more than 24 million individuals in the United States, including over 4.6 million children.

Asia Pacific is growing at the fastest pace in the global allergy treatment market

Asia Pacific region is expected to grow at the fastest pace over the forecast period. The increasing prevalence of allergies and increased research and development activities of various products help drive the market in this region.

For instance, according to the National Institute of Health, Asthma is estimated to affect 37.5 million people in India, and recent research shows that the prevalence of allergic rhinitis and asthma is increasing. Approximately 40-50% of pediatric asthma cases in India are uncontrolled or severe. Due to increases in allergies, the demand for allergy treatment is increasing day by day making this region the fastest-growing region in the forecast period.

Market Segmentation

By Allergy Type

  • Eye Allergy
  • Food Allergy
  • Skin Allergy
  • Asthma
  • Rhinitis
  • Others

By Treatment Type

  • Anti-Allergy Drugs
    • Antihistamines
    • Corticosteroids
    • Leukotriene Inhibitors
    • Others
  • Immunotherapy
    • Subcutaneous Immunotherapy
    • Sublingual Immunotherapy

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the global allergy treatment market include GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Stallergenes Greer, Allergy Therapeutics, Sanofi, Sumitomo Pharma Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc. among others.

Emerging Players

Angany Inc., DBV Technologies, and Vedanta Biosciences, Inc. among others.

Key Developments

  • In February 2024, the U.S. Food and Drug Administration approved Xolair (omalizumab) injection for immunoglobulin E-mediated food allergy in certain adults and children 1 year or older for the reduction of allergic reactions (Type I), including reducing the risk of anaphylaxis, that may occur with accidental exposure to one or more foods.

Why Purchase the Report?

  • To visualize the global allergy treatment market segmentation based on allergy type, treatment type, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of global allergy treatment market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping is available in Excel consisting of key products of all the major players.

The global allergy treatment market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Allergy Type
  • 3.2. Snippet by Treatment Type
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Allergies across the Globe
    • 4.1.2. Restraints
      • 4.1.2.1. Side Effects Associated with the Medication
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs
  • 5.6. PESTEL Analysis
  • 5.7. Patent Analysis
  • 5.8. SWOT Analysis

6. By Allergy Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Allergy Type
    • 6.1.2. Market Attractiveness Index, By Allergy Type
  • 6.2. Eye Allergy*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Food Allergy
  • 6.4. Skin Allergy
  • 6.5. Asthma
  • 6.6. Rhinitis
  • 6.7. Others

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.1.2. Market Attractiveness Index, By Treatment Type
  • 7.2. Anti-Allergy Drugs*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Immunotherapy

8. By Distribution Channel

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.1.2. Market Attractiveness Index, By Distribution Channel
  • 8.2. Hospital Pharmacy*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Retail Pharmacy
  • 8.4. Online Pharmacy
  • 8.5. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Allergy Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. The U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Allergy Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. UK
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Allergy Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Allergy Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Allergy Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. GlaxoSmithKline plc *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Teva Pharmaceutical Industries Ltd.
  • 11.3. Stallergenes Greer
  • 11.4. Allergy Therapeutics
  • 11.5. Sanofi
  • 11.6. Sumitomo Pharma Inc.
  • 11.7. Johnson & Johnson Services Inc.
  • 11.8. Merck & Co. Inc.
  • 11.9. F.Hoffman -La Roche
  • 11.10. Abbvie Inc.

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us